NCT05559671View on ClinicalTrials.gov

Safety of the Herpes Zoster Subunit Vaccine in Lupus

PHASE4RecruitingINTERVENTIONAL
Enrollment

224

Participants

Timeline

Start Date

December 21, 2023

Primary Completion Date

January 31, 2027

Study Completion Date

January 31, 2027

Conditions
Systemic Lupus Erythematosus
Interventions
BIOLOGICAL

Herpes Zoster Subunit (HZ/su) Vaccine

Manufactured by GSK Biologicals SA. Administered as two-time injection of 0.5 mL each at either weeks 0 and 8 or weeks 24 and 32.

BIOLOGICAL

Placebo

Saline injection. Administered as two-time injection of 0.5 mL each at either weeks 0 and 8 or weeks 24 and 32.

Trial Locations (2)

10016

RECRUITING

NYU Langone Health, New York

73104

RECRUITING

Oklahoma Medical Research Foundation, Oklahoma City

All Listed Sponsors
lead

NYU Langone Health

OTHER